CYTOMX THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.59 USD | -0.62% |
|
-4.79% | +2.58% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 377.6 | 302.8 | 282.5 | 105.7 | 103.8 | 107.7 | - | - |
| Enterprise Value (EV) 1 | 189.1 | -13.35 | 282.5 | 105.7 | 103.8 | 107.7 | 107.7 | 107.7 |
| P/E ratio | -3.68 x | -9.23 x | -3.33 x | -1.06 x | -155 x | -5.49 x | -4.21 x | -2.66 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.57 x | 3.02 x | 4.06 x | 1.99 x | 1.03 x | 1.15 x | 1.48 x | 2.32 x |
| EV / Revenue | 6.57 x | 3.02 x | 4.06 x | 1.99 x | 1.03 x | 1.15 x | 1.48 x | 2.32 x |
| EV / EBITDA | -3.49 x | -6.58 x | -3.48 x | - | - | -1.68 x | -1.09 x | - |
| EV / FCF | -2.62 x | - | -2.34 x | -0.94 x | - | -2.05 x | -1.91 x | -8.28 x |
| FCF Yield | -38.1% | - | -42.7% | -106% | - | -48.7% | -52.5% | -12.1% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 45,434 | 46,224 | 65,249 | 66,084 | 66,989 | 67,732 | - | - |
| Reference price 2 | 8.310 | 6.550 | 4.330 | 1.600 | 1.550 | 1.590 | 1.590 | 1.590 |
| Announcement Date | 2/27/20 | 2/24/21 | 3/1/22 | 3/27/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 57.49 | 100.4 | 69.57 | 53.16 | 101.2 | 94.02 | 72.9 | 46.4 |
| EBITDA 1 | -108.3 | -46.03 | -81.08 | - | - | -64.16 | -98.59 | - |
| EBIT 1 | -110.9 | -48.6 | -83.78 | -101.3 | -6.484 | -32.76 | -57.27 | -75.38 |
| Operating Margin | -192.9% | -48.43% | -120.42% | -190.61% | -6.41% | -34.85% | -78.56% | -162.46% |
| Earnings before Tax (EBT) 1 | -102.7 | -46.8 | -83.61 | -99.32 | 3.323 | -24.45 | -43.35 | -70.72 |
| Net income 1 | -102.2 | -32.88 | -83.61 | -99.32 | -0.569 | -24.49 | -43.39 | -70.76 |
| Net margin | -177.84% | -32.77% | -120.17% | -186.82% | -0.56% | -26.05% | -59.52% | -152.49% |
| EPS 2 | -2.260 | -0.7100 | -1.300 | -1.510 | -0.0100 | -0.2897 | -0.3781 | -0.5967 |
| Free Cash Flow 1 | -144 | - | -120.6 | -112.5 | - | -52.5 | -56.5 | -13 |
| FCF margin | -250.44% | - | -173.4% | -211.67% | - | -55.84% | -77.5% | -28.02% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/24/21 | 3/1/22 | 3/27/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 17.59 | 19.73 | 17.14 | 18.16 | 16.92 | 0.946 | 23.5 | 24.72 | 26.38 | 26.61 | 22.42 | 21.72 | 21.92 | 25.34 | 3 |
| EBITDA 1 | - | - | -23.36 | - | - | - | - | - | - | - | -9 | -13 | -17 | -25 | - |
| EBIT 1 | -22.64 | -26.31 | -23.97 | -24.74 | -23.94 | -28.68 | -5.653 | -3.348 | 3.123 | -0.606 | -3.58 | -4.774 | -7.07 | -11.93 | - |
| Operating Margin | -128.74% | -133.36% | -139.86% | -136.21% | -141.54% | -3,032.24% | -24.06% | -13.54% | 11.84% | -2.28% | -15.97% | -21.98% | -32.25% | -47.09% | - |
| Earnings before Tax (EBT) 1 | -22.58 | -26.23 | -23.88 | -24.18 | -23.3 | -27.95 | -3.311 | -1.087 | 5.815 | 1.906 | -3.064 | -4.247 | -6.523 | -10.62 | - |
| Net income 1 | -22.58 | -26.23 | -23.88 | -24.18 | -23.3 | -27.95 | -3.311 | -1.087 | 2.992 | 0.837 | -3.073 | -4.249 | -6.523 | -10.62 | - |
| Net margin | -128.41% | -132.95% | -139.38% | -133.14% | -137.72% | -2,954.76% | -14.09% | -4.4% | 11.34% | 3.15% | -13.71% | -19.56% | -29.76% | -41.9% | - |
| EPS 2 | -0.3500 | -0.4000 | -0.3700 | -0.3700 | -0.3500 | -0.4200 | -0.0500 | -0.0200 | 0.0400 | 0.0100 | -0.0409 | -0.0530 | -0.0813 | -0.1195 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/1/22 | 5/5/22 | 8/4/22 | 11/8/22 | 3/27/23 | 5/9/23 | 8/8/23 | 11/7/23 | 3/11/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 188 | 316 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -144 | - | -121 | -113 | - | -52.5 | -56.5 | -13 |
| ROE (net income / shareholders' equity) | - | - | -120% | - | - | - | -178% | - |
| ROA (Net income/ Total Assets) | - | - | -24% | -33.1% | - | -27.5% | -30.4% | - |
| Assets 1 | - | - | 349 | 300.2 | - | 89.16 | 142.9 | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 3.5 | - | 1.61 | 1.74 | - | - | - | - |
| Capex / Sales | 6.08% | - | 2.31% | 3.27% | - | - | - | - |
| Announcement Date | 2/27/20 | 2/24/21 | 3/1/22 | 3/27/23 | 3/11/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
1.59
USD
Average target price
2.9
USD
Spread / Average Target
+82.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.58% | 108M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CTMX Stock
- Financials CytomX Therapeutics, Inc.
